# Gilead will pay $3.15 billion upfront in cash, and up to $1.85 billion more if certain milestones are met.

*business · news · 2026-04-07 · Bloomberg*

## Key points

- Gilead Sciences will acquire Tubulis GmbH for up to $5 billion.
- The deal includes a $3.15 billion upfront cash payment and $1.85 billion in milestone payments.
- Tubulis specializes in a new area of cancer drug development.
- The acquisition is expected to close in the second quarter of this year.

**Companies:** Gilead Sciences Inc., Tubulis GmbH
**Countries:** Germany, United States

[Read the full story on Bloomberg](https://www.bloomberg.com/news/articles/2026-04-07/gilead-agrees-to-buy-cancer-biotech-tubulis-in-5-billion-deal)

---

Canonical: https://newsio.io/n/383f5319-9500-4928-8b46-da721571d15b/gilead-will-pay-3-15-billion-upfront-in-cash-and-up-to-1-85-billion-more-if-cert
Summarized by Newsio from Bloomberg. https://newsio.io/how-it-works